Privacy Policy
Contact Us
Toggle navigation
About EOM
About EOM
Our Mission
Our Values
Our Story
Our Team
Relentless Science
Powering Relentless Science
Powering Relentless Science
The Legacy and Potential of EOM613
The History of EOM613
Our Focus
Serving Patients
Our Focus: Serving Patients
Infectious Disease/COVID-19
Cancer Cachexia
Rheumatoid Arthritis
Retinal Diseases
EOM Pipeline
EOM Pipeline
Pipeline Chart
Clinical Trials
Clinical Trials
Published Articles
News & Media
News & Media
Media Kit
News
Press Releases
Investors
Powering Relentless Science
™
Powering Relentless Science
™
About EOM
About EOM
Our Mission
Our Values
Our Story
Our Team
Relentless Science
Powering Relentless Science
Powering Relentless Science
The Legacy and Potential of EOM613
The History of EOM613
Our Focus
Serving Patients
Our Focus: Serving Patients
Infectious Disease/COVID-19
Cancer Cachexia
Rheumatoid Arthritis
Retinal Diseases
EOM Pipeline
EOM Pipeline
Pipeline Chart
Clinical Trials
Clinical Trials
Published Articles
News & Media
News & Media
Media Kit
News
Press Releases
Investors
EOM_Pharma_Name_Change_Press_RELEASE_ANNOUNCEMENT_11.10.22_FINAL
